XML 107 R89.htm IDEA: XBRL DOCUMENT v3.25.0.1
Legal Settlements and Loss Contingencies - Additional Information (Detail)
€ in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Nov. 30, 2020
EUR (€)
Loss Contingencies [Line Items]        
Legal settlements and loss contingencies, expenses $ 761 $ 1,043 $ 2,082  
Accrued amount for legal settlements and loss contingencies $ 4,881 $ 4,771   € 60.5
Opioid Litigation [Member] | United States [Member]        
Loss Contingencies [Line Items]        
Restructuring expense and income Legal settlements and loss contingencies in 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE, and an update to the estimated settlement provision for the opioid cases (mainly the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore). Legal settlements and loss contingencies in 2023 were mainly related to an estimated provision for the DOJ patient assistance program litigation, an update to the estimated settlement provision of the opioid cases, the provision for the settlement of the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, as well as the provision for the settlement of the reverse-payment antitrust litigation over certain HIV medicines. Legal settlements and loss contingencies in 2022 were mainly related to updates of the estimated settlement provision recorded in connection with the remaining opioid cases.